UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

You're on page 37, See the latest articles on Artificial Intelligence. The Microsoft leak, which stemmed from AI researchers sharing open-source training data on GitHub, has been mitigated. Users ...

imperial.ac.uk Rationale Heart failure (HF) management in chronic obstructive pulmonary disease (COPD) is often delayed or suboptimal. Objectives To examine the effect of HF and HF medication use on ...

hli.ubc.ca Background There is limited data on the risk factors and phenotypical characteristics associated with spirometrically confirmed COPD in never-smokers in the general population. Aims To ...